On March 22, 2022, Cleveland BioLabs reported obtained a limited waiver ("Waiver") from a certain investor ("Investor") with respect to certain provisions of a Securities Purchase Agreement, dated as of February 6, 2022, by and among the Company and the Investor which limits the ability of the Company to issue common stock and/or warrants except through the confidentially marketed public offering announced on March 22, 2022 (Filing, 8-K, Cleveland BioLabs, MAR 22, 2022, View Source [SID1234610573]). As consideration for the limited waiver, upon consummation of such public offering, the exercise price of the Common Stock Purchase Warrant issued on February 9, 2022, by the Company to the Investor in connection with the Securities Purchase Agreement, will be repriced from $1.00 per share to the public offering price per Unit in the confidentially marketed public offering of the Company, subject to adjustment under the Common Stock Purchase Warrant.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On March 22, 2022 Philochem, a subsidiary of the Philogen Group, and Bracco Imaging reported that they have entered into a license and collaboration agreement to develop and commercialize a small organic molecule for imaging applications, with proven ability to selectively detect a variety of metastatic solid tumors in cancer patients, paving the way for a new approach to tumor diagnosis (Press release, Philogen, MAR 22, 2022, View Source(003).pdf [SID1234610598]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Philogen and Bracco share an Italian heritage and operate globally in the pharmaceutical and biotech sectors. Bracco and Philochem will pioneer the development of cutting-edge technologies for the discovery and optimization of small molecule ligands that enable unprecedented specificity and sensitivity for the imaging of solid tumors.

Prof. Dr. Dario Neri, Member of the Board of Philochem and CEO of the Philogen Group, commented: "We are extremely pleased to establish a new collaboration with Bracco Imaging, a leading global company in the image diagnostics field. This new collaboration will focus on the development and commercialization of a small molecule for imaging applications, which promises to improve the diagnosis, staging and monitoring of response-to-treatment for cancer patients. Both companies are committed to the development of the product and making it available to patients who may benefit from it."

"We are very excited about this collaboration with Philochem, a leader in the discovery and development of novel pharmaceutical and biopharmaceutical products. It demonstrates Bracco’s commitment to long-term value creation in medical imaging. Over the years, Bracco has built a portfolio of leading products across all imaging modalities and is continuing to invest in innovation to shape the future of precision imaging and improve people’s lives", commented Fulvio Renoldi Bracco, Vice-Chairman & CEO of Bracco Imaging.

On March 22, 2022 KSQ Therapeutics (KSQ), a clinical-stage biotechnology company developing therapies to treat cancer and autoimmune diseases using its proprietary, integrated discovery CRISPRomics platform, reported that will give an oral presentation as part of the "New Drugs on the Horizon: Part 1" session at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) 2022 Annual Meeting in New Orleans (Press release, KSQ Therapeutics, MAR 22, 2022, View Source [SID1234610615]). The company will provide an overview of preclinical data on its first-in-class USP1 inhibitor, KSQ-4279, which supports the ongoing Phase 1 clinical trial of KSQ-4279 being conducted in patients with advanced solid tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Title: ND01 – KSQ-4279: A first-in-class USP1 inhibitor for the treatment of cancers with homologous recombination deficiencies
Session Title: DDT001 – New Drugs on the Horizon: Part 1
Session Date and Time: Sunday, April 10, 2022, 1:05-1:20 pm CT
Location: La Nouvelle Orleans A-B, Convention Center

Data Highlights:

First disclosure of KSQ-4279 structure, a potent and selective USP1 inhibitor
KSQ-4279 has a unique mode of allosteric binding to USP1 and a high degree of selectivity over other family members
Efficacy was observed both as a single agent and in combination with PARP inhibitors across multiple BRCA/HRD xenograft models
Functional genomic resistance screens indicate that the major genetic drivers of resistance to USP1 and PARP inhibitors are distinct, indicating that combination treatment may be able to delay or prevent the emergence of resistance
Favorable safety profile without overlapping toxicities suggests broad combination potential with PARP inhibitors
"Based on the preclinical data we have observed from our studies of KSQ-4279, we believe it has great potential in a number of solid tumors, and we are looking forward to sharing the results from our ongoing Phase 1 clinical study in the future," said Frank Stegmeier, Ph.D., Chief Scientific Officer of KSQ. "USP1 is the first of multiple exciting targets that our CRISPRomics platform identified. In addition to KSQ-4279, we’re advancing multiple engineered TIL (eTILTM) adoptive cell therapy programs towards the clinic."

KSQ-4279

KSQ-4279 is a first-in-class small molecule targeting USP1, a protein regulating DNA damage response (DDR). USP1 was identified by KSQ’s CRISPRomics platform as a novel synthetic lethal target in cancers with certain types of genomic instability. KSQ-4279 is currently in a Phase 1 study in patients with advanced solid tumors.

On March 22, 2022 Coherus BioSciences, Inc. ("Coherus", Nasdaq: CHRS), reported that Coherus plans to host an Analyst Day on March 29, 2022 at 9:30 a.m. ET in New York City (Press release, Coherus Biosciences, MAR 22, 2022, View Source [SID1234610574]). Coherus executives and scientists will provide updates on the preparation for multiple potential new product launches anticipated over the next 15 months as well as the Company’s transformational entry into immuno-oncology with PD-1 inhibitor toripalimab and innovative PD-1 combination candidates.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors and analysts who would like to attend the Coherus Analyst Day event in-person or virtually may pre-register here.

A live webcast of the Analyst Day will be available on the Events & Presentations page of the Coherus website at View Source Please access the website prior to the start of the event to ensure a timely connection to the webcast. A replay of the event will be archived on the Coherus website for 30 days.

On March 22, 2022 Pionyr Immunotherapeutics, Inc., a company developing first-in-class Myeloid TuningTM antibody therapeutics that enhance the body’s antitumor immunity by altering, or "tuning", immune cells within the tumor microenvironment, reported preclinical results from its PY265 program demonstrating efficacy both as single-agent and in combination with anti-PD1 (Press release, Pionyr Immunotherapeutics, MAR 22, 2022, View Source [SID1234621641]). The latest preclinical research from the program was presented in a poster at the Keystone Symposium titled Cancer Immunotherapy: Decoding the Cancer Immunity Interactome and in a talk today, March 22.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"PY265 further demonstrates our Myeloid Tuning platform by engaging the macrophage receptor, MARCO, to repolarize immunosuppressive myeloid populations in the tumor and induce rapid immune activation," said Kevin P. Baker, Ph.D., SVP and Chief Development Officer at Pionyr. "Our lead programs, PY314 (anti-TREM2) and PY159 (anti-TREM1), are currently in the clinic, and PY265 is on track to complete IND-enabling studies and enter the clinic in 2023."

PY265 targets the macrophage receptor with collagenous structure (MARCO), leveraging a distinct mechanism of action from other myeloid-directed therapeutics currently in development and is expected to be first-in-class. MARCO is expressed on immunosuppressive tumor associated macrophages (TAMs) and monocytic myeloid-derived suppressor cells (mMDSCs), and its expression correlates with aggressive and advanced disease. These subpopulations of tumor myeloid cells are different from those that express the targets of Pionyr’s current lead clinical programs, TREM1 and TREM2. By targeting MARCO, PY265 induces immune activation by reprogramming pro-tumorigenic, M2-like TAMs and mMDSCs to pro-inflammatory macrophages and monocytes, leading to an increase in intra-tumoral infiltration of activated CD8+ T cells and NK cells.

The poster presentation is available on the company website at View Source